Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1951 1
1956 1
1958 1
1970 1
1974 2
1981 1
1982 3
1983 2
1984 1
1985 1
1987 2
1988 3
1989 2
1990 1
1992 2
1993 2
1995 1
1996 2
1997 1
1998 2
1999 1
2001 1
2003 3
2004 4
2005 1
2007 2
2008 4
2009 1
2010 1
2011 2
2012 1
2013 1
2014 2
2015 3
2016 3
2017 1
2019 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC. Woyach JA, et al. Among authors: savage re. Cancer Discov. 2024 Jan 12;14(1):66-75. doi: 10.1158/2159-8290.CD-23-0670. Cancer Discov. 2024. PMID: 37930156 Clinical Trial.
Occupational applications of a human cancer research model.
Savage RE Jr, DeBord DG, Swaminathan S, Butler MA, Snawder J, Kanitz MH, Cheever K, Reid T, Werren D. Savage RE Jr, et al. J Occup Environ Med. 1998 Feb;40(2):125-35. doi: 10.1097/00043764-199802000-00008. J Occup Environ Med. 1998. PMID: 9503288 Review.
Priorities for development of research methods in occupational cancer.
Ward EM, Schulte PA, Bayard S, Blair A, Brandt-Rauf P, Butler MA, Dankovic D, Hubbs AF, Jones C, Karstadt M, Kedderis GL, Melnick R, Redlich CA, Rothman N, Savage RE, Sprinker M, Toraason M, Weston A, Olshan AF, Stewart P, Zahm SH; National Occupational Research Agenda Team. Ward EM, et al. Among authors: savage re. Environ Health Perspect. 2003 Jan;111(1):1-12. doi: 10.1289/ehp.111-1241299. Environ Health Perspect. 2003. PMID: 12524210 Free PMC article. Review.
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.
Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Darling TN, Burton-Akright J, Bagheri M, Dombi E, Gruber A, Jarosinski PF, Martin S, Nathan N, Paul SM, Savage RE, Wolters PL, Schwartz B, Widemann BC, Biesecker LG. Keppler-Noreuil KM, et al. Among authors: savage re. Am J Hum Genet. 2019 Mar 7;104(3):484-491. doi: 10.1016/j.ajhg.2019.01.015. Epub 2019 Feb 22. Am J Hum Genet. 2019. PMID: 30803705 Free PMC article. Clinical Trial.
A Bayesian network model for biomarker-based dose response.
Hack CE, Haber LT, Maier A, Shulte P, Fowler B, Lotz WG, Savage RE Jr. Hack CE, et al. Among authors: savage re jr. Risk Anal. 2010 Jul;30(7):1037-51. doi: 10.1111/j.1539-6924.2010.01413.x. Epub 2010 Apr 20. Risk Anal. 2010. PMID: 20412521
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
Lapierre JM, Eathiraj S, Vensel D, Liu Y, Bull CO, Cornell-Kennon S, Iimura S, Kelleher EW, Kizer DE, Koerner S, Makhija S, Matsuda A, Moussa M, Namdev N, Savage RE, Szwaya J, Volckova E, Westlund N, Wu H, Schwartz B. Lapierre JM, et al. Among authors: savage re. J Med Chem. 2016 Jul 14;59(13):6455-69. doi: 10.1021/acs.jmedchem.6b00619. Epub 2016 Jun 29. J Med Chem. 2016. PMID: 27305487
65 results